37324
HIKMA PHARMACEUTICALS PUBLIC LIMITED COMPANY
Dec 21, 2017
Jordan
Middle East
Jun 9, 2017
B - Limited
Active
Jun 12, 2021
Regional Industry - MAS ME & Africa
Health, Education and Life Sciences
Approved : Jun 23, 2017
Signed : Dec 21, 2017
Invested : Apr 28, 2020
Pharmaceuticals and Medicine
Hikma Pharmaceuticals PLC (“Hikma” or the “Company”) and its subsidiaries (the “Group”), is a generic pharmaceutical company incorporated in United Kingdom(“UK”)and listed on the London Stock Exchange (“LSE”). While the Group was founded in Jordan in 1978, Hikma has expanded its footprint with successful operations across the Middle East and North Africa (“MENA”) region, the United States (“US”) and Europe. The Company has 29 manufacturing facilities in 11 countries out of which facilities in 5 countries have received US Food and Drug Administration (“FDA”) approval. Hikma’s main business lines include branded, injectables and generic pharmaceuticals. Hikma is a long-standing IFC client since 1987.
The Company has invited IFC to provide and arrange financing to support the general corporate purposes of the Company and members of its Group in the MENA region and/or in other World Bank Group countries of operation.
For Inquiries About the Project, Contact
For Inquiries and Comments About IFC, Contact
Local Access of Project Documentation
Hikma will make relevant documentation available in Arabic and/or English on its website (www.hikma.com) and at each of its offices in the Jordan and London. Locations and contact information for Hikma facilities may be found at www.hikma.com.
Additional enquiries should be directed to:
Susan Ringdal
Investor Relations Director
Hikma Pharmaceuticals PLC
1 New Burlington Place,
London,
W1S 2HR,
United Kingdom.
Tel: +44 (0) 20 7399 2760
Fax: +44 (0) 20 7399 2761
Ibrahim Armouti Group Treasurer
Hikma Pharmaceuticals PLC
P.O. Box: 182400, Amman 11118, Jordan
Tel 962 6 5802900
Fax 962 6 5827107
Email:IArmouti@Hikma.com